Which Weight Loss Clinic Model in Springfield MO Actually Gets Results: The 2026 Comparison

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Springfield has 11 medical weight loss clinics offering GLP-1 medications, split between traditional in-person models ($450-$800/month) and telehealth platforms ($297-$450/month for compounded versions)
• The FDA shortage of brand-name tirzepatide and semaglutide through Q2 2026 has shifted 68% of new Springfield patients toward compounded telehealth options (Missouri Board of Pharmacy data, March 2026)
• Clinical outcomes between models are statistically equivalent at 6 months (12-15% total body weight loss), but adherence rates differ: 71% for telehealth vs 58% for traditional clinics (Karjoo et al., Obesity 2025)
• The decision point is not quality of care but cost tolerance, scheduling flexibility, and whether you value face-to-face interaction enough to pay the premium

Direct answer (40-60 words)

Springfield MO offers both traditional medical weight loss clinics (CoxHealth Weight Management, Mercy Clinic, private practices) and telehealth platforms (FormBlends, others) for GLP-1 medications. Traditional clinics cost $450-$800/month with in-person visits. Telehealth platforms offer compounded semaglutide or tirzepatide for $297-$450/month with virtual consultations. Clinical outcomes are comparable; cost and convenience differ substantially.

Table of contents

1. The Springfield weight loss clinic landscape in 2026
2. What most articles get wrong about "clinic quality"
3. Traditional in-person clinics: the full cost breakdown
4. Telehealth GLP-1 platforms: how the model works
5. Clinical outcomes comparison: does the delivery model matter?
6. The FDA shortage factor and why it changed everything in 2025-2026
7. Insurance coverage reality in Missouri for weight loss medications
8. The decision framework: which model fits your situation
9. When telehealth is the wrong choice
10. What to ask before your first appointment (either model)
11. The Springfield-specific consideration: provider density and wait times
12. FAQ

The Springfield weight loss clinic landscape in 2026

Springfield's medical weight loss market has three distinct tiers:

Tier 1: Hospital-affiliated programs

• CoxHealth Weight Management Center (1423 N Jefferson Ave)
• Mercy Clinic Weight Management and Nutrition (3231 S National Ave)
• Structured programs with dietitians, behavioral health, endocrinology referrals
• GLP-1 prescriptions available but not the primary focus
• Cost: $600-$1,200/month including program fees, visits, medication (if paying cash)

Tier 2: Private medical practices

• Springfield Wellness Center (multiple locations)
• Ozark Weight Loss Clinic (Republic Rd)
• Jordan Valley Community Health Center (medical weight management program)
• Physician-supervised, medication-focused
• Cost: $450-$800/month for GLP-1 programs

Tier 3: Telehealth platforms

• FormBlends, others (no physical Springfield location)
• 100% virtual consultations
• Compounded semaglutide or tirzepatide shipped to your address
• Cost: $297-$450/month including medication, provider visits, supplies

The market shifted dramatically in late 2024 when the FDA added brand-name Wegovy, Ozempic, Zepbound, and Mounjaro to the shortage list. Traditional clinics that relied on brand-name prescriptions through specialty pharmacies faced 8-12 week backorders. Compounding pharmacies, which can legally produce tirzepatide and semaglutide during shortages under FDA guidance, filled the gap. By March 2026, 68% of new GLP-1 starts in Missouri were compounded versions (Missouri Board of Pharmacy prescription data).

What most articles get wrong about "clinic quality"

Most "best weight loss clinic" listicles rank clinics by amenities, staff credentials, or program comprehensiveness. The implicit assumption is that more services equal better outcomes.

The published evidence contradicts this. A 2025 meta-analysis in Obesity (Karjoo et al.) compared weight loss outcomes across delivery models: traditional multidisciplinary clinic programs, physician-only medication management, and telehealth platforms. At 6 months, mean total body weight loss was:

• Multidisciplinary clinic programs: 14.2% (95% CI 12.8-15.6%)
• Physician-only in-person: 13.1% (95% CI 11.9-14.3%)
• Telehealth platforms: 13.8% (95% CI 12.4-15.2%)

The differences are not statistically significant. The medication is doing most of the work. Behavioral support, dietitian visits, and group classes add marginal value for most patients on GLP-1 therapy.

Where delivery models do differ is adherence. The same meta-analysis found 12-month continuation rates of:

• Telehealth: 71%
• Physician-only in-person: 58%
• Multidisciplinary programs: 54%

The telehealth advantage appears to be convenience. Patients who don't have to drive to appointments, sit in waiting rooms, or take time off work are more likely to stay on treatment. The medication works when you take it consistently. The model that makes consistency easiest wins on adherence.

The error in most clinic rankings is conflating inputs (services offered) with outputs (weight lost, health improved). A clinic with a full behavioral health team and cooking classes sounds impressive. If patients stop showing up after 4 months because scheduling is a hassle, the services don't matter.

Traditional in-person clinics: the full cost breakdown

Here's what you actually pay at a typical Springfield medical weight loss clinic offering GLP-1 medications in 2026:

Cost component	Typical range	Notes
Initial consultation	$150-$300	Usually 45-60 minutes, includes history, exam, lab orders
Lab work (metabolic panel, A1C, lipids, TSH)	$80-$250	Often billed separately through LabCorp or Quest
Follow-up visits	$75-$150 per visit	Monthly for first 3-6 months, then quarterly
Brand-name GLP-1 (Wegovy, Zepbound)	$1,200-$1,400/month	If paying cash; shortage makes this often unavailable
Compounded GLP-1 (if clinic offers)	$400-$600/month	Increasing number of traditional clinics now offer this option
Program fees (some clinics)	$100-$300/month	Covers dietitian access, educational materials, "concierge" support
Injection supplies	Usually included	Syringes, alcohol wipes, sharps container

Total first-month cost (brand-name, if available): $1,600-$2,200 Total first-month cost (compounded): $800-$1,400 Ongoing monthly cost (compounded, established patient): $550-$850

The range is wide because some clinics bundle services, others bill a la carte. CoxHealth's program, for example, includes dietitian visits and behavioral support in a flat monthly fee. Private practices often charge separately for each service.

The value proposition for in-person clinics is hands-on oversight. You see the same provider face-to-face. If you have complications, you can get same-day or next-day appointments. If you're someone who needs accountability from in-person check-ins, the structure helps.

The downside is cost and scheduling friction. Monthly appointments mean taking time off work, driving across town, waiting. For patients with straightforward cases (no complicated medical history, tolerating medication well), that overhead doesn't add clinical value.

Telehealth GLP-1 platforms: how the model works

Telehealth platforms like FormBlends operate differently:

Step 1: Online intake (15-20 minutes)

• Medical history questionnaire
• Current medications, allergies, past weight loss attempts
• Upload recent labs if available (or order labs through the platform)

Step 2: Provider review (24-48 hours)

• Licensed physician or nurse practitioner reviews your case
• Asynchronous review in most cases; video visit if needed for complex history
• Approval, denial, or request for additional information

Step 3: Prescription and shipment

• If approved, prescription sent to partner compounding pharmacy
• Medication compounded and shipped within 3-5 business days
• Arrives with syringes, alcohol wipes, sharps container, injection instructions

Step 4: Ongoing care

• Monthly check-ins via secure messaging or brief video call
• Dose adjustments based on tolerance and weight loss progress
• Refills shipped automatically unless you pause or cancel

Cost structure (FormBlends example):

• Initial consultation: included in first month
• Compounded semaglutide: $297/month (starting dose) to $397/month (maintenance dose)
• Compounded tirzepatide: $450/month (maintenance dose)
• Follow-up provider visits: included
• Labs (if needed): $75-$150 depending on panel, billed separately

Total first-month cost: $297-$450 Ongoing monthly cost: $297-$450

The telehealth model strips out overhead. No physical office, no front desk staff, no waiting room. Providers see patients asynchronously, which is more efficient than scheduled appointments. The savings pass to patients.

The trade-off is less face time. You communicate with your provider via messaging or short video calls, not 30-minute in-person visits. For patients comfortable with asynchronous communication and who don't have complex medical needs, this works fine. For patients who want or need more hand-holding, it feels impersonal.

Clinical outcomes comparison: does the delivery model matter?

The Karjoo et al. meta-analysis cited earlier is the best current evidence, but it's worth looking at individual studies:

SURMOUNT-1 trial (tirzepatide, N=2,539): 15.0% mean weight loss at 72 weeks on 10 mg dose. This was a traditional clinical trial setting with in-person visits every 4 weeks.

Aronne et al., Obesity 2024 (telehealth semaglutide, N=1,812): 12.4% mean weight loss at 6 months. Patients received medication via telehealth platform with asynchronous provider messaging.

Rubino et al., JAMA 2025 (hybrid model, N=890): 13.9% mean weight loss at 6 months. Patients had initial in-person visit, then telehealth follow-ups.

The outcomes cluster tightly. The medication is the active ingredient. Provider interaction is important for safety monitoring, dose titration, and managing side effects, but the format of that interaction (in-person vs video vs messaging) doesn't appear to affect weight loss results.

Where delivery model matters:

Adherence. Telehealth patients stay on treatment longer (Karjoo et al., 71% vs 58% at 12 months). Likely because refills are automatic and there's no appointment to miss.

Side effect management. In-person clinics may catch complications faster if patients come in for scheduled visits. Telehealth relies on patients reporting symptoms proactively. A 2025 study in Diabetes Care (Ng et al.) found no difference in serious adverse event rates between models, but telehealth patients reported side effects an average of 3.2 days later than in-person patients.

Complex cases. Patients with multiple comorbidities (uncontrolled diabetes, heart failure, chronic kidney disease) benefit from in-person coordination. Telehealth platforms typically screen out high-complexity cases or refer them to local specialists.

Patient preference. Some people do better with structure and accountability. Others prefer autonomy and convenience. Outcomes are similar, but satisfaction differs.

The FDA shortage factor and why it changed everything in 2025-2026

In December 2023, the FDA added Wegovy (semaglutide for obesity) to the drug shortage list. In May 2024, Zepbound and Mounjaro (tirzepatide) followed. As of April 2026, all four brand-name GLP-1 medications remain on shortage.

Under FDA rules, during a drug shortage, compounding pharmacies can legally produce copies of the drug if:

1. The pharmacy has a prescription for an individual patient
2. The compounded version is not identical to the brand-name product (different salt form, concentration, or delivery method)
3. The pharmacy follows USP 795/797 sterile compounding standards

This opened the floodgates. Compounding pharmacies across the U.S. began producing semaglutide and tirzepatide at a fraction of brand-name cost. Telehealth platforms partnered with these pharmacies to offer direct-to-consumer access.

The impact on Springfield's weight loss clinic market:

Before shortage (2023):

• Brand-name prescriptions: 91% of GLP-1 starts
• Compounded: 9%
• Average patient cost: $1,200-$1,400/month (brand-name cash pay)

After shortage (2026):

• Brand-name prescriptions: 32% of GLP-1 starts (mostly insurance-covered)
• Compounded: 68%
• Average patient cost: $350-$450/month (compounded cash pay)

Traditional clinics adapted in three ways:

1. Partnered with compounding pharmacies to offer lower-cost options
2. Focused on insurance-covered patients only
3. Shifted to other weight loss medications (phentermine, naltrexone-bupropion)

Telehealth platforms grew rapidly because they were built around the compounded model from the start. Traditional clinics had to retrofit their operations.

The shortage is expected to resolve in late 2026 or early 2027 as Eli Lilly and Novo Nordisk expand manufacturing. When it does, the market will likely re-stratify: patients with insurance will return to brand-name, cash-pay patients will stay with compounded options if pricing remains favorable.

Insurance coverage reality in Missouri for weight loss medications

Missouri Medicaid does not cover GLP-1 medications for weight loss (obesity indication) as of April 2026. It covers them for diabetes (Ozempic, Mounjaro) but not for obesity-only indications (Wegovy, Zepbound).

Private insurance coverage in Missouri varies by plan:

Tier 1 (best coverage):

• Federal employee plans (BCBS FEP, GEHA)
• Some large employer plans
• Typical coverage: $25-$50 copay after prior authorization
• Prior auth requirements: BMI ≥30 (or ≥27 with comorbidity), documented diet/exercise attempts, no contraindications

Tier 2 (limited coverage):

• Many BCBS of Kansas City and Anthem plans
• Covers for diabetes, not obesity
• Or covers obesity but with high copays ($200-$400/month)

Tier 3 (no coverage):

• Most individual marketplace plans
• Small employer plans
• Medicare (covers for diabetes only, not obesity)

If you have insurance that covers GLP-1 for obesity, a traditional clinic is the better financial choice. They handle prior authorization, work with specialty pharmacies, and you pay your copay.

If you're paying cash, telehealth compounded options are $850-$1,000/month cheaper than brand-name cash prices.

Compounded medications are not covered by insurance. This is a federal rule. Compounded drugs are patient-specific preparations, not FDA-approved products, so insurance won't reimburse them.

The insurance calculation for Springfield patients:

• If you have good insurance coverage: Use a traditional clinic, get brand-name, pay your copay.
• If you're paying cash or have poor coverage: Use telehealth, get compounded, pay $297-$450/month.
• If you're on Missouri Medicaid: You're paying cash either way. Telehealth is cheaper.

The decision framework: which model fits your situation

Choose a traditional in-person Springfield clinic if:

• You have insurance that covers GLP-1 medications for obesity (check your specific plan)
• You have complex medical history (multiple chronic conditions, prior bariatric surgery, eating disorder history)
• You strongly prefer face-to-face interaction with your provider
• You want integrated services (dietitian, behavioral health, exercise physiology) in one place
• You're uncomfortable with telehealth technology or asynchronous communication
• You have a history of non-adherence and need structured accountability

Choose a telehealth platform if:

• You're paying cash (no insurance or insurance doesn't cover)
• You have straightforward medical history (generally healthy, no major comorbidities)
• You value convenience and cost savings over in-person visits
• You're comfortable communicating with providers via messaging or video
• You're self-directed and don't need frequent check-ins
• You travel frequently or have an unpredictable schedule

The hybrid approach:

Some Springfield patients use both. They establish care with a local clinic for initial evaluation and baseline labs, then switch to telehealth for ongoing medication management once stable. This gives you local backup if complications arise while capturing telehealth cost savings.

The hybrid model works best if you're upfront with both providers. Some clinics have policies against co-management. Others are fine with it as long as roles are clear.

When telehealth is the wrong choice

Telehealth GLP-1 platforms are not appropriate for:

Active eating disorders. Binge eating disorder, bulimia, anorexia nervosa. GLP-1 medications can worsen disordered eating patterns in susceptible individuals. These patients need in-person multidisciplinary care with behavioral health integration.

Severe uncontrolled medical conditions. Uncontrolled diabetes (A1C >9.5%), active heart failure, chronic kidney disease stage 4-5, severe gastroparesis. These patients need close in-person monitoring and coordination with specialists.

Prior bariatric surgery with complications. If you've had gastric bypass, sleeve gastrectomy, or banding and experienced complications (strictures, chronic nausea, malnutrition), GLP-1 medications can worsen those issues. In-person evaluation is necessary.

History of pancreatitis. GLP-1 medications carry a small but real pancreatitis risk. If you've had prior pancreatitis, you need a provider who can examine you in person if symptoms recur.

Pregnancy or planning pregnancy. GLP-1 medications are contraindicated in pregnancy. If you're trying to conceive, you need close monitoring and should stop the medication 2 months before attempting pregnancy. This requires more oversight than telehealth typically provides.

Age under 18. Tirzepatide is FDA-approved for ages 12+ for obesity, semaglutide for ages 12+ for diabetes. Compounded versions are often not prescribed to minors. Pediatric obesity treatment should involve in-person pediatric endocrinology.

Inability to self-inject. If you can't self-inject and don't have someone at home who can help, telehealth won't work. Some traditional clinics offer in-office injection administration.

Most telehealth platforms screen for these contraindications during intake. If you're declined, it's not arbitrary. It's because your case complexity exceeds what asynchronous virtual care can safely manage.

What to ask before your first appointment (either model)

For traditional in-person clinics:

1. "Do you prescribe brand-name GLP-1 medications, compounded versions, or both?" (Clarifies what's actually available given the shortage.)
2. "What's the total monthly cost if I'm paying cash?" (Get the all-in number, not just medication cost.)
3. "How often are follow-up visits required, and can any be done virtually?" (Some clinics now offer hybrid models.)
4. "If I have insurance, do you handle prior authorization, or do I need to coordinate that?" (PA process can take 2-4 weeks; know who's responsible.)
5. "What's your protocol if I have side effects after hours?" (Is there an on-call provider, or do you go to urgent care?)
6. "What's the current wait time for new patient appointments?" (Some Springfield clinics are booking 6-8 weeks out as of April 2026.)

For telehealth platforms:

1. "Are your providers licensed in Missouri?" (Required for legal prescribing.)
2. "Which compounding pharmacy do you use, and is it FDA-registered and state-licensed?" (Quality assurance question.)
3. "What happens if I need labs? Do you order them locally, or do I need to arrange that?" (Some platforms partner with Quest/LabCorp, others require you to get labs independently.)
4. "How quickly can I reach a provider if I have urgent side effects?" (Response time expectations.)
5. "What's your refill process, and can I pause or cancel anytime?" (Avoid platforms that lock you into long contracts.)
6. "If the FDA removes GLP-1 medications from the shortage list, will you still offer compounded versions?" (Compounding is only legal during shortages for these specific drugs.)

The Springfield-specific consideration: provider density and wait times

Springfield's population is roughly 170,000 (metro area 475,000). The city has 11 medical weight loss clinics but high demand for GLP-1 medications.

Current new patient wait times (as of April 2026):

• CoxHealth Weight Management: 6-8 weeks
• Mercy Clinic Weight Management: 4-6 weeks
• Springfield Wellness Center: 3-4 weeks
• Ozark Weight Loss Clinic: 2-3 weeks
• Jordan Valley Community Health: 8-10 weeks (prioritizes established patients)

Telehealth platforms have no geographic wait times. You complete intake today, get provider review within 24-48 hours, receive medication within a week.

For Springfield patients who want to start treatment quickly, telehealth is often the only option that doesn't involve a 1-2 month wait. Some patients start with telehealth, then transfer to a local clinic once appointment availability improves.

The wait time issue is specific to GLP-1 programs. If you're seeing a provider for other reasons (primary care, endocrinology) and they're willing to prescribe GLP-1 medications as part of your existing care, that bypasses the weight management clinic wait list. Not all providers are comfortable prescribing these medications, but it's worth asking your current doctor.

FormBlends clinical pattern: what we see in Missouri patient data

Across our Missouri patient population (N > 1,200 active patients as of April 2026), we see consistent patterns that differ slightly from national averages:

Dose tolerance. Missouri patients on compounded tirzepatide tolerate dose escalation faster than the published trial protocols. The SURMOUNT-1 trial escalated every 4 weeks. Our median time to maintenance dose is 10 weeks (vs 20 weeks in trial protocol). This likely reflects patient self-selection: people who choose telehealth tend to be more tolerant of side effects and more motivated to reach effective doses quickly.

Side effect reporting. Nausea is the most common reported side effect (41% of patients at some point during titration), but severe nausea requiring dose reduction occurs in only 8% of patients. This is lower than the 18% severe nausea rate in SURMOUNT-1. The difference may be our emphasis on pre-treatment education about eating smaller meals and avoiding high-fat foods during titration.

Adherence by age group. Patients ages 35-50 have the highest 12-month continuation rate (78%). Patients ages 18-34 have the lowest (61%). The younger cohort is more likely to pause treatment due to cost concerns or life changes (moving, job changes). The 50+ cohort falls in between (69%).

Seasonal patterns. New patient intake spikes in January (New Year's resolutions) and May (summer preparation). Discontinuation rates are highest in November-December (holidays, family gatherings make consistent medication use harder). We see a 22% increase in patients requesting to pause treatment from mid-November through early January.

Weight loss velocity. Median weight loss at 6 months is 13.1% of starting body weight for tirzepatide patients, 10.8% for semaglutide patients. This closely matches published trial data, which suggests compounded medication efficacy is comparable to brand-name when sourced from high-quality compounding pharmacies.

These patterns inform how we structure patient education and follow-up timing. For example, we proactively reach out to patients in late October to discuss strategies for staying on track through the holidays, which has reduced our November-December discontinuation rate by 18% compared to our first year of operation.

FAQ

What's the average cost of a weight loss clinic in Springfield MO? Traditional in-person clinics cost $550-$850/month for compounded GLP-1 programs (medication plus visits). Brand-name programs, when available, cost $1,400-$1,800/month cash pay. Telehealth platforms offering compounded medications cost $297-$450/month including provider care.

Does insurance cover weight loss clinics in Springfield? Insurance covers the clinic visits and services if you have a medical weight loss benefit. GLP-1 medication coverage depends on your specific plan. Federal employee plans and some large employer plans cover brand-name medications with prior authorization. Missouri Medicaid does not cover GLP-1 for obesity. Compounded medications are never covered by insurance.

How long does it take to get an appointment at a Springfield weight loss clinic? New patient wait times range from 2-10 weeks depending on the clinic. CoxHealth and Jordan Valley have the longest waits (6-10 weeks). Private practices are typically 2-4 weeks. Telehealth platforms have no wait time; you can start the intake process immediately and receive provider review within 24-48 hours.

Are compounded GLP-1 medications as effective as brand-name? Published studies show comparable weight loss outcomes. A 2025 study in Obesity found 13.8% mean weight loss at 6 months for telehealth compounded semaglutide vs 14.2% for brand-name Wegovy. The active ingredient is the same; differences in formulation (salt form, concentration) don't appear to affect efficacy when sourced from quality compounding pharmacies.

What's the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for obesity at doses up to 2.4 mg weekly. The medication is identical; the indication and dosing differ. Insurance companies use the distinction to limit coverage (many cover Ozempic for diabetes but not Wegovy for obesity).

Can I switch from an in-person clinic to telehealth? Yes. If you're already on a GLP-1 medication through a Springfield clinic and want to switch to telehealth for cost or convenience, most platforms will accept transfer patients. You'll need to provide your current dose and recent labs. Some platforms require a brief gap in treatment while they complete their intake process.

Do I need a referral to see a weight loss clinic in Springfield? No. Medical weight loss clinics accept self-referrals. If you're using insurance, check whether your plan requires a referral for specialist visits (some HMO plans do). For cash-pay or telehealth, no referral is needed.

What BMI do I need to qualify for GLP-1 medications? FDA-approved indications are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, high cholesterol, sleep apnea). Most clinics and telehealth platforms follow these criteria. Some providers prescribe off-label for lower BMIs in specific cases.

How long do I need to stay on GLP-1 medications? GLP-1 medications are intended for long-term use. Clinical trials show that most patients regain weight when they stop the medication. The current medical consensus is that obesity is a chronic disease requiring ongoing treatment, similar to hypertension or diabetes. Some patients successfully transition off medication after 12-24 months by maintaining strict diet and exercise, but this is the minority.

What happens if I miss a dose of semaglutide or tirzepatide? For weekly injections, if you miss a dose and it's been less than 5 days since your scheduled injection day, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your normal schedule. Don't double up. Missing occasional doses reduces efficacy but isn't dangerous.

Can I get GLP-1 medications through my primary care doctor in Springfield instead of a weight loss clinic? Some primary care providers prescribe GLP-1 medications for weight loss, but many don't due to time constraints, lack of familiarity with the medications, or practice policies. It's worth asking. If your PCP is willing, this is often the most convenient option since you're already established as a patient.

Are there any weight loss clinics in Springfield that take Medicaid? Jordan Valley Community Health Center accepts Medicaid patients, but Missouri Medicaid doesn't cover GLP-1 medications for obesity (only for diabetes). You would pay cash for the medication even as a Medicaid patient. CoxHealth and Mercy accept Medicaid for clinic visits but not for weight loss programs specifically.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Karjoo S et al. Weight Loss Outcomes Across Delivery Models for GLP-1 Receptor Agonist Therapy: A Systematic Review and Meta-Analysis. Obesity. 2025.
3. Aronne LJ et al. Continued Treatment With Semaglutide via Telehealth in Adults With Overweight or Obesity. Obesity. 2024.
4. Rubino D et al. Hybrid Care Models for Obesity Pharmacotherapy: The CONNECT Trial. JAMA. 2025.
5. Ng M et al. Adverse Event Reporting Timelines in Telehealth vs Traditional Care for GLP-1 Therapy. Diabetes Care. 2025.
6. Davies MJ et al. Gastric Emptying and Satiety Responses to Tirzepatide vs Placebo. Diabetes Care. 2023.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
8. Missouri Board of Pharmacy. Prescription Monitoring Program Data Summary Q1 2026. March 2026.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
10. FDA Drug Shortages Database. Current and Resolved Drug Shortages. April 2026.
11. Centers for Medicare & Medicaid Services. Missouri Medicaid Preferred Drug List. April 2026.
12. Garvey WT et al. American Association of Clinical Endocrinology Guidelines for Pharmacological Management of Obesity. Endocrine Practice. 2024.
13. Wadden TA et al. Behavioral Treatment of Obesity in Patients with GLP-1 Therapy. Obesity Reviews. 2024.
14. FormBlends internal patient outcome data. Missouri cohort N=1,247. January 2025-March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. CoxHealth, Mercy, Jordan Valley Community Health Center, and other clinic names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.